Oncolytics Biotech Inc. (ONCY)
Oxford Ledge is still expanding full research coverage of ONCY. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
A clinical-stage biopharmaceutical company developing an immunotherapy virus for treating gastrointestinal cancers, dependent on partnerships and additional funding to advance development.
SEC filings
- 8-K Other material event 2026-07-13
- 8-K 4.01; Financial statements and exhibits 2026-07-08
- 8-K Other material event 2026-06-16
- 8-K Departure/election of directors or officers; Other material event 2026-06-02
- 8-K Other material event 2026-06-01
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for ONCY. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open ONCY in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.